AbbVie gets FDA approval for SKYRIZI subcutaneous induction regimen
AbbVie said the FDA approved a subcutaneous induction regimen for SKYRIZI for adults with moderately to severely active Crohn's disease. The regimen uses an on-body injector device.
Key points
- The company announced the approval on October 23.
- On October 27, AbbVie submitted a biologics license application to the FDA for etentamig.
- This overview relies on headlines and short excerpts from company announcements, not full texts.
What happened
The company announced the approval on October 23. According to AbbVie, the new regimen supports early control of symptoms and endoscopic results. For patients with Crohn's disease, the new regimen means a different way of giving the drug. The on-body injector is used throughout the course of treatment.
Another event: application for etentamig
On October 27, AbbVie submitted a biologics license application to the FDA for etentamig. The application covers adults with relapsed or refractory multiple myeloma. The company describes etentamig as a second-generation BCMA-directed bispecific antibody that engages T cells.
What the reports do not show
This overview relies on headlines and short excerpts from company announcements, not full texts. So clinical data, approval conditions and the review timeline for the application are not visible in these materials.
What to watch next
The next step for etentamig is the FDA's decision on the application. These materials give no review timeline, so it is worth following the company's official announcements.
For SKYRIZI, it is worth checking whether the new subcutaneous regimen appears in the company's explanations of drug sales. These materials contain no sales data.
Original sources
- U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
- AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow AbbVie
A notification in your browser or on your phone when we publish about AbbVie. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
